These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34285878)

  • 21. Adrenal Insufficiency Associated With Empty Sella Syndrome and Steroid Malabsorption Complicated With Septic Shock Due to Post-transplant Pyelonephritis: A Case Report.
    Shima H; Miya K; Okada K; Doi T; Minakuchi J
    Cureus; 2023 Apr; 15(4):e38234. PubMed ID: 37252555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone deficiency with late-onset hypothalamic hypoadrenocorticism associated with respiratory and renal dysfunction: a case report.
    Kojima N; Koriyama N; Tokito A; Ogiso K; Kusumoto K; Kubo S; Nishio Y
    BMC Endocr Disord; 2020 Apr; 20(1):50. PubMed ID: 32299407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia.
    Baldawi MB; Dhami B; Gosai J; Al-Khafaji RH
    Cureus; 2022 Aug; 14(8):e28393. PubMed ID: 36171843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus.
    Kurokawa M; Naito S; Ito S; Takai S; Kawamura Y; Kaneko H; Kakizaki H; Tsuchiya N
    IJU Case Rep; 2020 Sep; 3(5):181-183. PubMed ID: 32914068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated ACTH deficiency in a patient with empty sella as revealed by severe hyponatremia.
    Doroftei NA; de Rudder C; de Visscher N; Hanon F
    Acta Clin Belg; 2016 Dec; 71(6):451-454. PubMed ID: 27176077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report.
    Umihira S; Koyanagi T; Tamura K; Takahashi Y; Yoshiba T; Takahashi S; Taneichi A; Saga Y; Takei Y; Fujiwara H
    Exp Ther Med; 2022 Jun; 23(6):409. PubMed ID: 35619629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
    Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
    J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Primary empty sella associated with peripheral endocrine deficiency: two cases (author's transl)].
    Hazard J; Perlemuter L; Guilhaume B; Cenac A; Maury JR
    Nouv Presse Med; 1979 May; 8(21):1745-7. PubMed ID: 221883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Jpn J Clin Oncol; 2019 May; 49(5):473-476. PubMed ID: 30920617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report.
    Eguchi S; Shinkawa H; Sato Y; Nakai K; Takemura S; Tanaka S; Amano R; Kimura K; Ohira G; Nishio K; Kinoshita M; Tauchi J; Miyazaki T; Ishihara A; Shirai D; Kubo S
    Clin J Gastroenterol; 2021 Jun; 14(3):858-865. PubMed ID: 33811313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary empty sella, hyperprolactinemia, and isolated ACTH deficiency after postpartum hemorrhage.
    Stacpoole PW; Kandell TW; Fisher WR
    Am J Med; 1983 May; 74(5):905-8. PubMed ID: 6301277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
    Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
    J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.
    Seki T; Yasuda A; Oki M; Kitajima N; Takagi A; Nakajima N; Miyajima A; Fukagawa M
    Tokai J Exp Clin Med; 2017 Sep; 42(3):115-120. PubMed ID: 28871578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
    Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
    BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evans syndrome during pembrolizumab therapy for upper urinary tract cancer.
    Kakita S; Matsuo T; Ohki M; Tsuchiyama A; Yasuda T; Nakanishi H; Mitsunari K; Ohba K; Imamura R
    IJU Case Rep; 2023 Sep; 6(5):298-301. PubMed ID: 37667757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.